Literature DB >> 6713763

Ampicillin and propylthiouracil pharmacokinetics in intestinal bypass patients followed up to a year after operation.

J P Kampmann, H Klein, B Lumholtz, J E Mølholm Hansen.   

Abstract

The pharmacokinetics of ampicillin and prophylthiouracil were studied in 6 and 9 patients, respectively, before and several times up to a year after a shunt operation for extreme obesity. The drugs were given intravenously and orally making it possible to estimate the absolute bioavailability. The bioavailability of propylthiouracil (about 80%) was unchanged by the surgical procedure but the fraction of ampicillin (given as pivampicillin) absorbed decreased from a preoperative value of 109 +/- 44% to 44 +/- 30% 12 months after the bypass operation. Volumes of distribution transiently decreased in the postoperative period for ampicillin. Clearance was initially reduced for both ampicillin and propylthiouracil after operation but returned to normal values a year later. Half-lives of both drugs were unchanged. These results are compared with previous data on pharmacokinetics in intestinal shunt patients and a tabular review is presented. Although no general rules presently emerge from the data available, it seems prudent to closely monitor intestinal shunt patients on drug therapy by both laboratory and clinical methods.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6713763     DOI: 10.2165/00003088-198409020-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  39 in total

1.  Tuberculosis after jejunoileal bypass for obesity.

Authors:  J R Pickleman; L S Evans; J M Kane; R J Freeark
Journal:  JAMA       Date:  1975-11-17       Impact factor: 56.272

2.  Bile acid metabolism and intestinal bacterial flora after three types of intestinal shunt operation for obesity.

Authors:  P Danö; K Lenz; T Justesen
Journal:  Scand J Gastroenterol       Date:  1974-11       Impact factor: 2.423

3.  The pharmacokinetics of propylthiouracil.

Authors:  J Kampmann; L Skovsted
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-11

4.  The gastrointestinal absorption of digoxin in seven patients with gastric or small intestinal reconstructions.

Authors:  B Beermann; K Hellström; A Rosén
Journal:  Acta Med Scand       Date:  1973-04

5.  Surgical treatment of obesity.

Authors:  J H Payne; L T DeWind
Journal:  Am J Surg       Date:  1969-08       Impact factor: 2.565

6.  Morphological changes of the small intestine following jejuno-ileal shunt in obese subjects.

Authors:  G Fenyö; L Backman; D Hallberg
Journal:  Acta Chir Scand       Date:  1976

7.  Isoniazid and ethambutol absorption with jejunoileal bypass.

Authors:  R E Polk; M Tenenbaum; B Kline
Journal:  Ann Intern Med       Date:  1978-09       Impact factor: 25.391

8.  Absorption of anticonvulsants after jejunoileal bypass.

Authors:  D I Peterson; R W Zweig
Journal:  Bull Los Angeles Neurol Soc       Date:  1974-04

9.  Relationship between hepatic morphology and clinical and biochemical findings in morbidly obese patients.

Authors:  J L Manes; H B Taylor; G B Starkloff
Journal:  J Clin Pathol       Date:  1973-10       Impact factor: 3.411

10.  Absorption of orally administered digoxin after massive resection of the small bowel.

Authors:  M M Krausz; E Berry; U Freund; M Levy
Journal:  Am J Gastroenterol       Date:  1979-02       Impact factor: 10.864

View more
  11 in total

Review 1.  Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes.

Authors:  Adam S Darwich; Kathryn Henderson; Angela Burgin; Nicola Ward; Janet Whittam; Basil J Ammori; Darren M Ashcroft; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

Review 2.  Vitamin, mineral, and drug absorption following bariatric surgery.

Authors:  Ronald Andari Sawaya; Jane Jaffe; Lindsay Friedenberg; Frank K Friedenberg
Journal:  Curr Drug Metab       Date:  2012-11       Impact factor: 3.731

Review 3.  Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.

Authors:  P O'Connor; J Feely
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

Review 4.  Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics.

Authors:  D T Bearden; K A Rodvold
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

5.  Lithium toxicity after Roux-en-Y bariatric surgery.

Authors:  Deanna Musfeldt; Andrew Levinson; Jennifer Nykiel; Gerardo Carino
Journal:  BMJ Case Rep       Date:  2016-03-18

6.  Site-dependent small intestinal absorption of ranitidine.

Authors:  T Gramatté; E el Desoky; U Klotz
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 7.  Dosing of medications in morbidly obese patients in the intensive care unit setting.

Authors:  Brian L Erstad
Journal:  Intensive Care Med       Date:  2003-11-19       Impact factor: 17.440

Review 8.  Oral drug dosing following bariatric surgery: General concepts and specific dosing advice.

Authors:  Jurjen S Kingma; Desirée M T Burgers; Valerie M Monpellier; Marinus J Wiezer; Heleen J Blussé van Oud-Alblas; Janelle D Vaughns; Catherine M T Sherwin; Catherijne A J Knibbe
Journal:  Br J Clin Pharmacol       Date:  2021-06-03       Impact factor: 3.716

Review 9.  Nanotechnology as a tool to overcome the bariatric surgery malabsorption.

Authors:  Osaid Almeanazel; Fars Alanazi; Ibrahim Alsarra; Doaa Alshora; Faiyaz Shakeel; Ahmad Almnaizel; Mohammed Alahmed; Ehab Fouad
Journal:  Saudi Pharm J       Date:  2020-03-19       Impact factor: 4.330

10.  The influence of bariatric surgery on oral drug bioavailability in patients with obesity: A systematic review.

Authors:  Philip Carlo Angeles; Ida Robertsen; Lars Thomas Seeberg; Veronica Krogstad; Julie Skattebu; Rune Sandbu; Anders Åsberg; Jøran Hjelmesaeth
Journal:  Obes Rev       Date:  2019-06-24       Impact factor: 9.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.